Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581917 · ClinicalTrials.gov registry record
Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia
A clinical trial of Recurrent Adult Acute Myeloid Leukemia and Untreated Adult Acute Myeloid Leukemia, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 14
- Enrollment target
- 1
- Study location
NCT02581917 is a study of Recurrent Adult Acute Myeloid Leukemia and Untreated Adult Acute Myeloid Leukemia that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 14 participants, below the 54-participant average among 19 other Recurrent Adult Acute Myeloid Leukemia trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02581917, a study of Recurrent Adult Acute Myeloid Leukemia and Untreated Adult Acute Myeloid Leukemia, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This research trial studies metabolic changes in blood samples from patients with acute myeloid leukemia. Studying samples of blood from patients with acute myeloid leukemia in the laboratory may help doctors learn more about cancer and the development of drug resistance.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Cytology Specimen Collection Procedure
Study Locations (1)
North Carolina
- Comprehensive Cancer Center of Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-04-21 |
| Est. Completion | 2022-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02581917
The ClinicalTrials.gov registry entry for NCT02581917 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 54-participant average among 19 other Recurrent Adult Acute Myeloid Leukemia trials with a reported enrollment target (74% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Adult Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02581917 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02581917 about?
NCT02581917 is a clinical study titled "Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia". This research trial studies metabolic changes in blood samples from patients with acute myeloid leukemia. Studying samples of blood from patients with acute myeloid leukemia in the laboratory may help doctors learn more about cancer and the development of drug resistance.
What is the current status of trial NCT02581917?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2017-04-21. Estimated completion is 2022-04-30.
What conditions does trial NCT02581917 study?
This clinical trial studies the following conditions: Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia.
What interventions are being tested in trial NCT02581917?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytology Specimen Collection Procedure (OTHER).
Who is sponsoring clinical trial NCT02581917?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02581917 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
RECRUITING · Phase 1
-
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Recurrent Adult Acute Myeloid Leukemia
All registered trials for this condition
Untreated Adult Acute Myeloid Leukemia
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.